Daniel J Weisdorf

Medicine & Life Sciences

1. Cell Transplantation 100%
2. Graft vs Host Disease 92%
3. Transplants 72%
4. Bone Marrow 63%
5. Transplantation 57%
6. Unrelated Donors 56%
7. Bone Marrow Transplantation 55%
8. Allogeneic Cells 55%
9. Tissue Donors 45%
10. Acute Myeloid Leukemia 38%
11. Survival 37%
12. Homologous Transplantation 32%
13. Fetal Blood 31%
14. Hematopoietic Stem Cell Transplantation 31%
15. Recurrence 30%
16. Leukemia 28%
17. Precursor Cell Lymphoblastic Leukemia-Lymphoma 27%
18. Mortality 23%
19. Siblings 22%
20. Confidence Intervals 22%
21. Myelodysplastic Syndromes 15%
22. Autologous Transplantation 14%
23. Whole-Body Irradiation 14%
24. Natural Killer Cells 13%
25. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 13%
26. Cyclophosphamide 13%
27. Stem Cell Transplantation 13%
28. Therapeutics 12%
29. Peripheral Blood Stem Cells 12%
30. Survivors 12%
31. Incidence 11%
32. Mycophenolic Acid 9%
33. Drug Therapy 9%
34. Disease-Free Survival 9%
35. Infections 9%
36. Multiple Myeloma 9%
37. Transplant Recipients 9%
38. KIR Receptors 9%
39. Clinical Trials 8%
40. Hematologic Neoplasms 8%
41. Non-Hodgkin's Lymphoma 8%
42. fludarabine 8%
43. Allografts 7%
44. Cytomegalovirus 7%
45. Antilymphocyte Serum 7%
46. Cytogenetics 7%
47. HLA Antigens 7%
48. Lymphoma 6%
49. Hematopoietic Stem Cells 6%